PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
58.56
ESG score near Biotechnology median of 61.04. David Dodd would investigate if industry-standard ESG practices adequately address sector-specific risks.
54.57
Environmental score near Biotechnology median of 56.92. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
58.53
Social score 90-95% of Biotechnology median of 63.82. John Neff would demand higher returns to compensate for below-average stakeholder management.
62.59
Governance score near Biotechnology median of 62.17. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.